Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.